Chemomab Therapeutics Ltd. (NASDAQ:CMMB – Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 93,600 shares, a growth of 29.1% from the September 30th total of 72,500 shares. Based on an average daily volume of 276,500 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.7% of the company’s stock are short sold.
Chemomab Therapeutics Price Performance
Shares of CMMB stock opened at $1.44 on Wednesday. The company has a market cap of $15.91 million, a P/E ratio of -0.90 and a beta of 0.52. The stock’s 50-day moving average is $1.64 and its 200 day moving average is $1.20. Chemomab Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.55.
Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last issued its quarterly earnings data on Wednesday, August 21st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). During the same period in the previous year, the firm earned ($0.72) EPS. On average, analysts anticipate that Chemomab Therapeutics will post -1 EPS for the current year.
Chemomab Therapeutics Company Profile
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Further Reading
- Five stocks we like better than Chemomab Therapeutics
- 3 Small Caps With Big Return Potential
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- What is Put Option Volume?
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- What does consumer price index measure?
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.